DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Sensus Healthcare Highlights Publication Of Research On Long-Term Efficacy, Safety Of Superficial Radiation Therapy In 'Journal Of Drugs In Dermatology'

Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today

Benzinga · 03/03/2020 13:39

Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced that results from a retrospective study of non-melanoma skin cancer (NMSC) patients treated with superficial radiation therapy (SRT) were published in the February 2020 issue of Journal of Drugs in Dermatology.

The study showed a non-recurrence rate of 98.9% after 85 months in 516 patients with a total of 776 NMSC lesions treated with SRT. Patients were treated with the SRT-100™ system marketed by Sensus Healthcare at four clinical sites prior to January 2015.  The article, “Long-Term Efficacy and Safety of Superficial Radiation Therapy in Subjects With Nonmelanoma Skin Cancer: A Retrospective Registry Study,” was authored by the following:

William Roth, M.D. of Dermatology and Dermatological Surgery, Boynton Beach, Fla.
Robert E. Beer, M.D. of Balfour Dermatology, Brentwood, Calif.
Vivek Iyengar, M.D. of Dermatology Associates, Tinley Park, Ill.
Thomas Bender, M.D., of Advanced Dermatology and Skin Care Centre, Mobile, Ala.
Isabelle Raymond, Ph.D.
Similar recurrence rates after 60 months were previously presented at the Annual Meeting of the American Academy of Dermatology in March 2019, and data from a similar retrospective study involving only the lower extremities were published in this same journal in February 2019.

An abstract of the article is available here.

“We are delighted that the powerful findings from this study were published in such an important journal, which will provide additional support to our sales representatives when discussing the benefits of SRT with potential physician customers,” said Joe Sardano, Sensus Healthcare’s chairman and chief executive officer. “Dr. Roth presented five-year topline findings from this study last year, and the complete, whole-body results are now available to physicians in this peer-reviewed journal.”

Most patients in the study population were elderly with a mean age of 79 years. Overall cure rates were consistent at 98.9% at 24, 60 and 85 months.  The Kaplan-Meier survival probability estimate was 0.989 at 24, 60 and 85 months, with a 95% confidence interval. The authors concluded that SRT is an effective and well-tolerated treatment for NMSC, and further state that these results add to the existing evidence demonstrating the safety and long-term efficacy of SRT for treating NMSC.